NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment Options

Metabolites, Journal Year: 2024, Volume and Issue: 14(7), P. 366 - 366

Published: June 28, 2024

Nonalcoholic fatty liver disease (NAFLD) poses an emerging threat topublic health. steatohepatitis (NASH) is reported to be the most rapidly rising cause of hepatocellular carcinoma in western world. Recently, a new term has been proposed: metabolic dysfunction-associated steatotic (MASLD). The introduction this terminology sparked debate about interchangeability these terms. pathogenesis NAFLD/MASLD thought multifactorial, involving both genetic and environmental factors. Among factors, alterations gut microbiota dysbiosis have recently garnered significant attention. In context, review will further discuss gut-liver axis, which refers bidirectional interaction between human liver. Additionally, therapeutic potential probiotics, particularly next-generation probiotics genetically engineered bacteria, explored. Moreover, role prebiotics, synbiotics, postbiotics, phages as well fecal transplantation analyzed. Particularly for lean patients with NAFLD/MASLD, who limited treatment options, approaches that modify diversity composition may hold promise. However, due ongoing safety concerns modulate microbiota, large-scale studies are necessary better assess their efficacy treating NAFLD/MASLD.

Language: Английский

---

Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2023, Volume and Issue: 24(6), P. 1189 - 1204

Published: Oct. 16, 2023

Language: Английский

---

Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

BMC Gastroenterology, Journal Year: 2024, Volume and Issue: 24(1)

Published: Aug. 22, 2024

There is a contradiction in the use of microbiota-therapies, including probiotics, prebiotics, and synbiotics, to improve condition patients with nonalcoholic fatty liver disease (NAFLD). The aim this review was evaluate effect microbiota-therapy on injury, inflammation, lipid levels individuals NAFLD. Using Pubmed, Embase, Cochrane Library, Web Science databases were searched for articles prebiotic, probiotic, or synbiotic treatment NAFLD up March 2024. Thirty-four studies involving 12,682 included. Meta-analysis indicated that supplementation significantly improved injury (hepatic fibrosis, SMD = -0.31; 95% CI: -0.53, -0.09; aspartate aminotransferase, -0.35; -0.55, -0.15; alanine -0.48; -0.71, -0.25; alkaline phosphatase, -0.81; -1.55, -0.08), profiles (triglycerides, -0.22; -0.43, -0.02), inflammatory factors (high-density lipoprotein, -0.47; -0.88, -0.06; tumour necrosis factor alpha, -0.86 -1.56, -0.56). Overall, had positive reducing enzymes, profiles, cytokines

Language: Английский

---

The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota

Life, Journal Year: 2024, Volume and Issue: 14(2), P. 239 - 239

Published: Feb. 8, 2024

Recent studies have shown the promising potential of probiotics, especially bacterial genus Bifidobacterium, in treatment liver diseases. In this work, a systematic review was conducted, with focus on that employed advanced Next Generation Sequencing (NGS) technologies to explore Bifidobacterium as probiotic for treating pathologies such Non-Alcoholic Fatty Liver Disease (NAFLD), Steatohepatitis (NASH), Alcoholic (ALD), Cirrhosis, and Hepatocelullar Carcinoma (HCC) its impact microbiota. Our results indicate is safe effective lesions. It successfully restored balance intestinal microbiota improved biochemical clinical parameters NAFLD, ALD, Cirrhosis. No significant adverse effects were identified. While more research needed establish efficacy NASH HCC, evidence suggests managing

Language: Английский

---

Roles of Traditional and Next-Generation Probiotics on Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review and Network Meta-Analysis

Antioxidants, Journal Year: 2024, Volume and Issue: 13(3), P. 329 - 329

Published: March 7, 2024

Non-alcoholic fatty liver disease (NAFLD) and its progressive stage, non-alcoholic steatohepatitis (NASH), are becoming one of the most common chronic diseases globally. Lifestyle interventions such as weight reduction, increased physical activity, maintaining healthy diets play a pivotal role in managing NAFLD/NASH. Recent studies suggest that gut microbiome is associated with pathogenesis NAFLD/NASH, prompting microbiome-targeted therapy to emerge new therapeutic option for We conducted systematic review based on PRISMA statement employed network meta-analysis investigate effects traditional probiotics next-generation (NGPs) Comparative analysis reveals primarily reduce fat deposition inflammation by improving microbiota composition, enhancing intestinal barrier function, modulating immune responses. In contrast, NGPs demonstrate more significant potential, attributed their direct inhibiting oxidative stress ability enhance production short-chain acids (SCFAs), appear potential strategy management NAFLD/NASH through dual action directly SCFA production, highlighting importance understanding utilizing indirect regulatory mechanisms

Language: Английский

---

Intestinal Barrier Impairment, Preservation, and Repair: An Update

Nutrients, Journal Year: 2024, Volume and Issue: 16(20), P. 3494 - 3494

Published: Oct. 15, 2024

Our objective was to review published studies of the intestinal barrier and permeability, deleterious effects dietary components (particularly fat), impact altered permeability in disease models human diseases, role microbiome epigenomics control function, opportunities restore normal function with interventions products microbiota.

Language: Английский

---

Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity

Foods, Journal Year: 2024, Volume and Issue: 13(18), P. 2992 - 2992

Published: Sept. 21, 2024

In recent years, the prevalence of non-alcoholic fatty liver disease (NAFLD) has risen annually, yet due to intricacies its pathogenesis and therapeutic challenges, there remains no definitive medication for this condition. This review explores intricate relationship between intestinal microbiome NAFLD, emphasizing substantial roles played by

Language: Английский

---

The effect of gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review and network meta-analysis

Frontiers in Nutrition, Journal Year: 2025, Volume and Issue: 11

Published: Jan. 6, 2025

The incidence of NAFLD is increasing. Preclinical evidences indicate that modulation the gut microbiome could be a promising target in nonalcoholic fatty liver disease. A systematic review and network meta-analysis was conducted to compare effect probiotics, synbiotics, prebiotics, fecal microbiota transplant, antibiotics on liver-enzyme, metabolic effects liver-specific patients with NAFLD. randomized controlled trails (RCTs), limited English language were searched from database such as Pubmed, Embase, Web science Cochrane Library inception November 2024. Review Manager 5.3 used draw bias risk. Inconsistency test publication-bias assessed by Stata 14.0. Random model assemble direct indirect evidences. intervention presented mean differences 95% confidence interval. total 1921 37 RCTs eventually included our study. 23 evaluated 10 4 3 FMT one RCT antibiotics. Probiotics synbiotics associated significantly reduction alanine aminotransferase [ALT, (MD: -5.09; 95%CI: -9.79, -0.39), -7.38, 95CI%: -11.94, -2.82)] stiffness measurement elastograph [LSM, -0.37;95%CI: -0.49, -0.25), -1.00;95%CI: -1.59, -0.41)]. In addition to, superior probiotics reducing LSM. Synbiotics significant Controlled Attenuation Parameter [CAP, -39.34; -74.73, -3.95)]. Both aspartate transaminase [AST, -7.81; -15.49, -0.12), -13.32; -23, -3.64)]. Allogenic Homeostatic Model Assessment for Insulin Resistance [HOMA-IR, -0.7, -1.26, -0.15), -1.8, -3.53, - 0.07)]. body mass index [BMI, MD: -1.84, -3.35, -0.33]. supplement maybe way improve LSM, steatosis More trials are needed determine efficacy And adverse events MTTs should further explored. https://www.crd.york.ac.uk/prospero/, CRD42023450093.

Language: Английский

---

Application of intelligent tongue image analysis in Conjunction with microbiomes in the diagnosis of MAFLD

Heliyon, Journal Year: 2024, Volume and Issue: 10(7), P. e29269 - e29269

Published: April 1, 2024

Metabolic associated fatty liver disease (MAFLD) is a widespread that can lead to fibrosis and cirrhosis. Therefore, it essential develop early diagnosic screening methods.

Language: Английский

---

A randomized, double-blinded, placebo-controlled clinical trial on Lactobacillus-containing cultured milk drink as adjuvant therapy for depression in irritable bowel syndrome

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: April 25, 2024

Irritable bowel syndrome (IBS) is frequently linked with coexisting mental illnesses. Our previous study discovered that 32.1% of IBS patients had subthreshold depression (SD), placing them at higher risk developing major depression. Gut microbiota modulation through psychobiotics was found to influence via the gut-brain axis. However, efficacy lessening among remains ambiguous. The study's aim investigate roles cultured milk drinks containing 10

Language: Английский

---